Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

548

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

November 3, 2023

Study Completion Date

February 28, 2024

Conditions

Ankylosing Spondylitis

Interventions

DRUG

SHR-1314

SHR-1314 high dose

DRUG

SHR-1314

SHR-1314 low-dose

DRUG

Placebo

Trial Locations (1)

Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY